Novo Nordisk files for regulatory approval of liraglutide 3 mg for the treatment of obesity

Bagsværd, Denmark, 20 December 2013 - Novo Nordisk today announced two separate regulatory submissions for a 3 mg dose of liraglutide, a once-daily human GLP-1 analogue, as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with obesity, or who are overweight with comorbidities. The company filed a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) and a Marketing Authorisation Application (MAA) with the European Medicines Agency (EMA).

Further information

Company announcement No 78 / 2013